Literature DB >> 33652377

The phenomics and genetics of addictive and affective comorbidity in opioid use disorder.

Philip J Freda1, Jason H Moore2, Henry R Kranzler3.   

Abstract

Opioid use disorder (OUD) creates significant public health and economic burdens worldwide. Therefore, understanding the risk factors that lead to the development of OUD is fundamental to reducing both its prevalence and its impact. Significant sources of OUD risk include co-occurring lifetime and current diagnoses of both psychiatric disorders, primarily mood disorders, and other substance use disorders, and unique and shared genetic factors. Although there appears to be pleiotropy between OUD and both mood and substance use disorders, this aspect of OUD risk is poorly understood. In this review, we describe the prevalence and clinical significance of addictive and affective comorbidities as risk factors for OUD development as a basis for rational opioid prescribing and OUD treatment and to improve efforts to prevent the disorder. We also review the genetic variants that have been associated with OUD and other addictive and affective disorders to highlight targets for future study and risk assessment protocols.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Comorbidity; Genetics; OUD; Opioids; Phenomics

Mesh:

Substances:

Year:  2021        PMID: 33652377      PMCID: PMC8059867          DOI: 10.1016/j.drugalcdep.2021.108602

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  157 in total

1.  Sequence and stages in patterns of adolescent drug use.

Authors:  D Kandel; R Faust
Journal:  Arch Gen Psychiatry       Date:  1975-07

2.  Depression and prescription opioid misuse among chronic opioid therapy recipients with no history of substance abuse.

Authors:  Alicia Grattan; Mark D Sullivan; Kathleen W Saunders; Cynthia I Campbell; Michael R Von Korff
Journal:  Ann Fam Med       Date:  2012 Jul-Aug       Impact factor: 5.166

3.  The OPRD1 and OPRK1 loci in alcohol or drug dependence: OPRD1 variation modulates substance dependence risk.

Authors:  H Zhang; H R Kranzler; B-Z Yang; X Luo; J Gelernter
Journal:  Mol Psychiatry       Date:  2007-07-10       Impact factor: 15.992

4.  Personality disparity in chronic regional and widespread pain.

Authors:  Mei-Chung Chang; Po-Fei Chen; For-Wey Lung
Journal:  Psychiatry Res       Date:  2017-04-27       Impact factor: 3.222

5.  Tobacco, cocaine, and heroin: Craving and use during daily life.

Authors:  David H Epstein; Gina F Marrone; Stephen J Heishman; John Schmittner; Kenzie L Preston
Journal:  Addict Behav       Date:  2009-11-12       Impact factor: 3.913

6.  [Personality in the big five model and maintaining abstinence after one year follow-up].

Authors:  Barbara Betkowska-Korpała
Journal:  Psychiatr Pol       Date:  2012 May-Jun       Impact factor: 1.657

Review 7.  Psychosocial interventions for psychostimulant misuse.

Authors:  Silvia Minozzi; Rosella Saulle; Franco De Crescenzo; Laura Amato
Journal:  Cochrane Database Syst Rev       Date:  2016-09-29

8.  Comparison of the Big Five personality traits in fibromyalgia and other rheumatic diseases.

Authors:  Emilie Bucourt; Virginie Martaillé; Denis Mulleman; Philippe Goupille; Isabelle Joncker-Vannier; Brigitte Huttenberger; Christian Reveillere; Robert Courtois
Journal:  Joint Bone Spine       Date:  2016-06-03       Impact factor: 4.929

9.  Genome-wide Association Study Identifies a Regulatory Variant of RGMA Associated With Opioid Dependence in European Americans.

Authors:  Zhongshan Cheng; Hang Zhou; Richard Sherva; Lindsay A Farrer; Henry R Kranzler; Joel Gelernter
Journal:  Biol Psychiatry       Date:  2018-01-11       Impact factor: 13.382

10.  Genome-wide association study of alcohol consumption and use disorder in 274,424 individuals from multiple populations.

Authors:  Henry R Kranzler; Hang Zhou; Rachel L Kember; Rachel Vickers Smith; Amy C Justice; Scott Damrauer; Philip S Tsao; Derek Klarin; Aris Baras; Jeffrey Reid; John Overton; Daniel J Rader; Zhongshan Cheng; Janet P Tate; William C Becker; John Concato; Ke Xu; Renato Polimanti; Hongyu Zhao; Joel Gelernter
Journal:  Nat Commun       Date:  2019-04-02       Impact factor: 14.919

View more
  2 in total

Review 1.  Novel digital approaches to the assessment of problematic opioid use.

Authors:  Philip J Freda; Henry R Kranzler; Jason H Moore
Journal:  BioData Min       Date:  2022-07-15       Impact factor: 4.079

2.  Hypothesizing in the Face of the Opioid Crisis Coupling Genetic Addiction Risk Severity (GARS) Testing with Electrotherapeutic Nonopioid Modalities Such as H-Wave Could Attenuate Both Pain and Hedonic Addictive Behaviors.

Authors:  Ashim Gupta; Abdalla Bowirrat; Luis Llanos Gomez; David Baron; Igor Elman; John Giordano; Rehan Jalali; Rajendra D Badgaiyan; Edward J Modestino; Mark S Gold; Eric R Braverman; Anish Bajaj; Kenneth Blum
Journal:  Int J Environ Res Public Health       Date:  2022-01-04       Impact factor: 3.390

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.